Switzerland’s Gold Industry Plans US Expansion
Switzerland is looking to bolster its gold industry by possibly establishing refineries in the United States or enhancing its processing capabilities. This move comes in tandem with efforts to address the trade tariffs imposed by the US, as per two sources familiar with the discussions.
President Trump recently enacted a 39% tariff on Swiss imports, citing a trade deficit with Switzerland that largely stems from Swiss exports, particularly in gold, chemicals, and pharmaceuticals. Since these tariffs were implemented, both the Swiss government and private businesses have been collaborating to find ways to reduce them.
As a major player in gold refining, part of Switzerland’s strategy involves increasing its refining capacity within the US, which could help balance trade flows. This might involve investments in new refineries and expanding operational capabilities in the country.
The Swiss Ministry of Economy confirmed that confidential negotiations with US representatives are ongoing, though they have refrained from sharing specific details.
Christoph Wild, president of the Swiss Precious Metals Association, chose not to comment on the specifics of the refinery plan. However, he emphasized that the industry needs to find solutions if gold continues to contribute to the trade deficit: “This may even be about meeting our demand from within the US,” he mentioned.
Last Friday, the Swiss Economic Minister, Guy Palmelin, characterized a meeting with Trump’s economic advisors as “constructive.” At that meeting, the gold plan was discussed, and sources indicate that negotiations are still active.
In an effort to address the trade deficit linked to pharmaceuticals, Swiss firms aspire to fulfill all US demand for their products through domestic manufacturing. Some sources suggest that additional production might even enable Swiss pharmaceutical companies to export from the US.
Switzerland is also hopeful that its pharmaceutical sector might receive exemptions from looming tariffs related to a separate US investigation into whether dependence on foreign drug production poses a national security risk.
The Swiss Pharmaceutical Industry Association Interharma remarked that, when services are factored in, there isn’t actually a trade deficit. They cautioned that overly restricting products to mitigate shortages might negatively impact the Swiss economy. Still, local production could shift focus to larger markets. While enhancing US capacity could alleviate pressure on Switzerland, it might compromise its position as a key drug hub.
Furthermore, there are discussions around increasing US military procurement and facilitating US sales to Switzerland, particularly through liquefied natural gas. Plans may also involve directing more energy transactions through Switzerland rather than London to help balance trade.
